As 2026 approaches, the clinical research and development landscape is evolving beyond traditional scientific innovation with ...
Examine the rise of personalized and biomarker-driven therapies, the logistical challenges of rare patient populations, and ...
ICON’s June 2025 survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and ...
Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in ...
At present evidence-based medicine is guided by the rules and regulations particularly of ethics and moral rights given which ...
With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, ...
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical ...
Gintemetostat showed promising activity in heavily pretreated, triple-class refractory multiple myeloma, including high-risk t(4;14) patients. The phase 1 study reported a tolerable safety profile, ...
The pharmaceutical and medical device industries stand at an inflection point. After decades of reliance on traditional ...
Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical ...
Digit health technologies (DHT) are a key aspect of U.S. Health & Human Services (HHS) Secretary Robert F. Kennedy Jr.’s Make America Healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback